Literature DB >> 33100201

Inhibition of Virulence Factors and Biofilm Formation of Acinetobacter Baumannii by Naturally-derived and Synthetic Drugs.

Nilushi Indika Bamunuarachchi1,2, Fazlurrahman Khan3,4, Young-Mog Kim1,3.   

Abstract

Acinetobacter baumannii is a gram-negative, aerobic, non-motile, and pleomorphic bacillus. A. baumannii is also a highly-infectious pathogen causing high mortality and morbidity rates in intensive care units. The discovery of novel agents against A. baumannii infections is urgently needed due to the emergence of drug-resistant A. baumannii strains and the limited number of efficacious antibiotics available for treatment. In addition to the production of several virulence factors, A. baumannii forms biofilms on the host cell surface as well. Formation of biofilms occurs through initial surface attachment, microcolony formation, biofilm maturation, and detachment stages, and is one of the major drug resistance mechanisms employed by A. baumannii. Several studies have previously reported the efficacy of naturally-derived and synthetic compounds as anti- biofilm and anti-virulence agents against A. baumannii. Here, inhibition of biofilm formation and virulence factors of A. baumannii using naturally-derived and synthetic compounds are reviewed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Acinetobacter baumannii; anti-biofilm; antivirulence; compounds; multiple drug-resistant; synthetic

Mesh:

Substances:

Year:  2021        PMID: 33100201     DOI: 10.2174/1389450121666201023122355

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   2.937


  144 in total

Review 1.  Acinetobacter baumannii: an emerging multidrug-resistant pathogen in critical care.

Authors:  Kerry Montefour; Jeanne Frieden; Sue Hurst; Cindy Helmich; Denielle Headley; Mary Martin; Deborah A Boyle
Journal:  Crit Care Nurse       Date:  2008-02       Impact factor: 1.708

Review 2.  Treatment of multidrug resistant Acinetobacter.

Authors:  Clinton K Murray; Duane R Hospenthal
Journal:  Curr Opin Infect Dis       Date:  2005-12       Impact factor: 4.915

Review 3.  Current molecular methods in epidemiological typing of Acinetobacter baumannii.

Authors:  Rayane Rafei; Marie Kempf; Matthieu Eveillard; Fouad Dabboussi; Monzer Hamze; Marie-Laure Joly-Guillou
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

Review 4.  Clinical impact and pathogenicity of Acinetobacter.

Authors:  M-L Joly-Guillou
Journal:  Clin Microbiol Infect       Date:  2005-11       Impact factor: 8.067

Review 5.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 6.  Uncovering the mechanisms of Acinetobacter baumannii virulence.

Authors:  Christian M Harding; Seth W Hennon; Mario F Feldman
Journal:  Nat Rev Microbiol       Date:  2017-12-18       Impact factor: 60.633

Review 7.  Acinetobacter baumannii: an emerging opportunistic pathogen.

Authors:  Aoife Howard; Michael O'Donoghue; Audrey Feeney; Roy D Sleator
Journal:  Virulence       Date:  2012-05-01       Impact factor: 5.882

8.  Deciphering the multifactorial nature of Acinetobacter baumannii pathogenicity.

Authors:  Luísa C S Antunes; Francesco Imperi; Alessandra Carattoli; Paolo Visca
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

9.  Role of the BaeSR two-component system in the regulation of Acinetobacter baumannii adeAB genes and its correlation with tigecycline susceptibility.

Authors:  Ming-Feng Lin; Yun-You Lin; Hui-Wen Yeh; Chung-Yu Lan
Journal:  BMC Microbiol       Date:  2014-05-09       Impact factor: 3.605

10.  Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors:  Bin Cai; Roger Echols; Glenn Magee; Juan Camilo Arjona Ferreira; Gareth Morgan; Mari Ariyasu; Takuko Sawada; Tsutae Den Nagata
Journal:  Open Forum Infect Dis       Date:  2017-08-16       Impact factor: 3.835

View more
  3 in total

1.  COVID-19 Clinical Profiles and Fatality Rates in Hospitalized Patients Reveal Case Aggravation and Selective Co-Infection by Limited Gram-Negative Bacteria.

Authors:  Kamaleldin B Said; Ahmed Alsolami; Safia Moussa; Fayez Alfouzan; Abdelhafiz I Bashir; Musleh Rashidi; Rana Aborans; Taha E Taha; Husam Almansour; Mashari Alazmi; Amal Al-Otaibi; Luluh Aljaloud; Basmah Al-Anazi; Ahmed Mohialdin; Ahmed Aljadani
Journal:  Int J Environ Res Public Health       Date:  2022-04-26       Impact factor: 4.614

2.  Prevalence of lipase producer Aspergillus niger in nuts and anti-biofilm efficacy of its crude lipase against some human pathogenic bacteria.

Authors:  Asmaa S Yassein; Mohamed M Hassan; Rokaia B Elamary
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379

Review 3.  Anti-Biofilm Molecules Targeting Functional Amyloids.

Authors:  Leticia Matilla-Cuenca; Alejandro Toledo-Arana; Jaione Valle
Journal:  Antibiotics (Basel)       Date:  2021-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.